Patients with advanced ovarian cancer that comes back or keeps growing after platinum chemotherapy often have very few treatment options, and it has been hard to achieve long-lasting control of the disease. Early results presented at ASCO 2026 from a new experimental treatment called IMA203CD8 are showing encouraging signs that this may change for some patients in the future.
IMA203CD8 is a personalized immune therapy. It uses a patient’s own T cells (a type of immune cell), which are collected, modified in a lab to better recognize cancer, and then given back as a one-time treatment. This therapy targets a protein called PRAME, which is found mostly on cancer cells.
Why these early results are encouraging
In a small group of patients with advanced ovarian cancer who had already gone through several treatments, doctors saw encouraging responses:
- Tumors shrank in most patients studied
- About half of the patients had a response (meaning the cancer clearly got smaller)
- Many patients had disease control, where the cancer stopped growing or slowed down
Importantly, many of these responses were still ongoing when the data were reported. Some lasted up to a year or longer, which is especially meaningful in this stage of cancer, where long-lasting responses are difficult to achieve.
What this could mean for patients
For patients, when tumors shrink or stop growing, it can often mean:
- Fewer or milder symptoms
- More time before the next treatment is needed
- A better quality of life
Because this therapy is given once, there is also the possibility of a longer treatment-free period, which is important for patients who have already been through many rounds of therapy.
Why this is different from other treatments
Ovarian cancer has been difficult to treat with immunotherapy in the past. This therapy is different because it can recognize a target inside the cancer cell (PRAME) by using the body’s immune system in a more precise way. Researchers also believe it may help “wake up” the immune system inside the tumor, making it easier for immune cells to attack cancer.
What happens next
These results are still early, and more research is needed. The next step is to find the best dose of the treatment and study it in more patients to better understand:
- How long responses last
- How safe and effective it is over time
- Whether it may help other cancers that also express PRAME
Bottom line
While still in early testing, IMA203CD8 is showing promising signs of helping some patients with advanced ovarian cancer whose disease has stopped responding to standard treatments. The fact that some patients are seeing responses lasting a year or longer is especially encouraging in this setting, where durable control has historically been difficult.
Want a summary of ASCO 2026 ovarian cancer highlights? Here’s an overview of key takeaways from this year’s event.
